Literature DB >> 8297715

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.

E Erba1, S Sen, C Sessa, F L Vikhanskaya, M D'Incalci.   

Abstract

Inhibition of clonogenic potential by the glycinamideribonucleosyl transformylase inhibitor 5,10-dideazatetrahydrofolic acid (DDATHF, Lometrexol) was evaluated in vitro in a human ovarian carcinoma cell line, SW626. Drug-induced inhibition of clonogenic potential is a function of the dose and time of exposure and is independent of the formation of DNA single-strand breaks or de novo synthesis of protein. Simultaneous treatment with 100 microM hypoxanthine completely prevented the inhibition of clonogenic potential caused by 0.5 microM DDATHF. DDATHF blocked cells in the early-middle S-phases of the cell cycle, and there was a corresponding marked reduction in the rate of DNA synthesis after drug withdrawal. The cytotoxic potential of DDATHF was modulated by the folic acid concentration present in the medium. In a medium containing 0.22 microM folic acid, DDATHF cytotoxicity was at least 100 times that in a regular medium containing 2.22 microM folic acid, levels which, however, are about 100 times those found in human plasma. DDATHF cytotoxicity differed moderately when folic acid concentrations varied between 0.22 and 0 microM, suggesting that folic acid does not necessarily antagonise DDATHF anti-tumour activity. Folinic acid at a concentration as low as 0.1 microM can completely rescue cells when given simultaneously with 0.5 microM DDATHF. When folinic acid was given 24 h after DDATHF, a reversal of cytotoxicity was observed at 0.5 and 1 microM, but to a much lesser extent than simultaneous treatment. When folinic acid was added after 48 or 72 h of DDATHF washout, even at a high concentration and for a long time, no reduction in DDATHF cytotoxicity was found. In conclusion, the study highlights the modulation of DDATHF cytotoxicity by folic acid or by folinic acid and provides further rationale for in vivo clinical investigation with these combinations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8297715      PMCID: PMC1968679          DOI: 10.1038/bjc.1994.40

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  The biological chemistry of folate receptors.

Authors:  A C Antony
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

2.  Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.

Authors:  G Jansen; G R Westerhof; I Kathmann; G Rijksen; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.

Authors:  E C Taylor; J M Hamby; C Shih; G B Grindey; S M Rinzel; G P Beardsley; R G Moran
Journal:  J Med Chem       Date:  1989-07       Impact factor: 7.446

4.  Folate-binding protein is a marker for ovarian cancer.

Authors:  I G Campbell; T A Jones; W D Foulkes; J Trowsdale
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

5.  (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.

Authors:  G Pizzorno; B A Moroson; A R Cashmore; G P Beardsley
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

6.  Expression of a folate binding protein in L1210 cells grown in low folate medium.

Authors:  G Jansen; I Kathmann; B C Rademaker; B J Braakhuis; G R Westerhof; G Rijksen; J H Schornagel
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

7.  Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.

Authors:  G R Westerhof; G Jansen; N van Emmerik; I Kathmann; G Rijksen; A L Jackman; J H Schornagel
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

8.  Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin.

Authors:  E Erba; S Sen; A Lorico; M D'Incalci
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

9.  Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.

Authors:  S W Baldwin; A Tse; L S Gossett; E C Taylor; A Rosowsky; C Shih; R G Moran
Journal:  Biochemistry       Date:  1991-02-19       Impact factor: 3.162

10.  DNA fragmentation, dATP pool elevation and potentiation of antifolate cytotoxicity in L1210 cells by hypoxanthine.

Authors:  J B Kwok; M H Tattersall
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

View more
  4 in total

1.  Automatic quantitation of cell colonies on petri dishes by computerized image analysis.

Authors:  A Bollea; M Masseroli; A Nicotra; P Beccaglia; S Sen; E Erba; G Balconi
Journal:  Cytotechnology       Date:  1995-10       Impact factor: 2.058

2.  Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.

Authors:  R N Turner; G W Aherne; N J Curtin
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Mode of action of thiocoraline, a natural marine compound with anti-tumour activity.

Authors:  E Erba; D Bergamaschi; S Ronzoni; M Faretta; S Taverna; M Bonfanti; C V Catapano; G Faircloth; J Jimeno; M D'Incalci
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

4.  Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.

Authors:  S Sen; E Erba; M D'Incalci; F Bottero; S Canevari; A Tomassetti
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.